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Modernization of therapy 
in patients with chronic 
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disease
Introduction
Today doctors are increasingly facing the so-
called comorbid course of chronic obstructive 
pulmonary disease (COPD) and ischemic 
heart disease (IHD), which is accompanied 
with the syndrome of mutual burdening and 
development of the “vicious circle”, which leads 
to deterioration of COPD and has a negative 
impact on the effectiveness of basic treatment 
[1-3]. Taking into account these circumstances, 
the considerable attention is paid to treatment of 
co-morbidities in the international consensuses 
and protocol of patients with COPD [4,5].
Most confirmed hypotheses consist in the 
fact that in such an association diseases are 
connected with common risk factors (active 
or passive smoking, adverse environmental 
conditions, respiratory tract infections) which 
cause chronic systemic inflammation by acting 
on vascular endothelial cells, airway epithelium, 
lung parenchyma [6].
The use of basic medications for the treatment 
of COPD, such as inhaled corticosteroids, 
has a pronounced anti-inflammatory effect 
on both the local and systemic levels, and it 
does not ensure the complete elimination of 
inflammation [3,7].
Taking into account the common risk factors 
and pathogenetic mechanisms in development 
of both diseases, increasing attention has been 
paid to the use of statins in treatment of COPD. 
This group of medications except the main 
one – of lipid-lowering action, has pleiotropic 
(anti-inflammatory, immunomodulatory, and 
antioxidant) effects, influencing not only the 
condition of the vascular wall, but also the 
diseases of respiratory system [2,4]. Under the 
influence of statins, a decrease in the level of 
systemic inflammation markers and C-reactive 
protein (CRP) occurs, by means of reducing the 
production of interleukin-6 [1].
The results of randomized multicenter studies 
demonstrated that statin therapy in high doses 
reduces the risk of mortality in patients with 
COPD, decreases exacerbations and slows the 
processes of emphysema development [8,9].
Thus, the use of statins in treatment of COPD 
combined with ischemic heart disease requires 
further study.
The aim of the research is to investigate the 
clinical efficacy of the use of rosuvastatin in 
treatment of COPD combined with ischemic 
heart disease.
Materials and Methods
We examined 30 patients with COPD of B 
group combined with ischemic heart disease 
(stable exertional angina of FC II) aged from 51 
to 67 (average age was 57.03 ± 3.51) who were 
hospitalized in the Pulmonology Department 
of Poltava regional clinical hospital named after 
Sklifosovsky. The average duration of COPD in 
examined patients was between 10 and 15 years.
The diagnosis of COPD was established 
in accordance with the order of the Ministry 
of Public Health of Ukraine No 555 as of 
06.27.2013 [10] and the provisions set forth 
in the document GOLD (Global Initiative for 
Chronic Obstructive Lung Disease) [11]. IHD 
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admitted for inpatient treatment in pulmonology 
department of the Poltava Regional Clinical 
Hospital Sklifosovsky 05.15.16, complaining 
of periodical fever up to 37.5°C, usually in 
the evening, cough with sputum, significant 
shortness of breath, general weakness, marks a 
low exercise capacity, fatigue, lack of appetite, 
periodically arising heartaches [16].
  Objectively 
General state of moderate severity. In the 
lungs - vesicular breathing weakened. Heart rate-
96 beats per 1 mininutu, blood pressure-150/90 
mm hg. art. Abdomen soft, painless, the 
liver does not protrude from under the edge 
of the costal arch, the ECG left ventricular 
hypertrophy, diffuse violation of repolarization.
  The entering diagnosis
Chronic obstructive pulmonary disease 
combined with coronary heart disease. Patients 
were conducted comprehensive clinical and 
diagnostic examinations: blood tests, kidney 
tests, liver function tests - bilirubin, AST, 
ALT, total protein; coagulation, electrolytes, 
lipids, urinalysis, ECG, Echo-KS, abdominal 
ultrasound. Estimation of respiratory symptoms 
in points, exercise tolerance, external respiration 
function evaluation cholesterol, low density 
lipoproteins (LDL) and high density (HDL) 
lipoproteins.
After a thorough examination and diagnosis of 
COPD was assigned protocol therapy, namely: 
Serevent 25 mcg two inhalations twice a day, if 
necessary Aerofillin 0.4 g twice a day, ambroxol 
0.3 g twice a day and treatment protocol CHD 
comprising isosorbide dinitrate 20-40 mg/day, 
cardiomagnil 75 mg/day, 10 mg of rosuvastatin.
12 days after the treatment is carried out 
the repeated set of laboratory, clinical and 
instrumental studies: evaluation of respiratory 
symptoms in scores, exercise capacity, lung 
function, assessment of the level of cholesterol, 
low density lipoprotein and high-density 
lipoprotein.
After the treatment, the patient showed 
improvement of clinical condition by reducing 
the intensity of the severity of respiratory 
symptoms: cough, sputum, dyspnea and increase 
exercise tolerance and improve laboratory and 
instrumental performance (TABLE 1).
It was noted that regression of the respiratory 
symptoms in the main group of patients was 
more manifested in the comparative analysis of 
clinical symptoms between the groups. Thus, 
picture, medical history, ECG, and a six-minute 
walk test (SMWT) [12].
According to the aim of the study, all patients 
were divided into two groups. Patients were 
selected based on the “case-control” method, so 
that the groups were comparable in terms of age, 
COPD group, FC of stable angina.
Patients of the main groups (n=15) received 
COPD protocol therapy, namely 25 µg of 
serevent by two inhalations twice a day; if 
necessary, 0.4 g of aerofillin twice a day, 0.3 g of 
ambroxol twice a day. The protocol treatment 
of IHD included isosorbide- dinitrate at a dose 
of 20-40 mg/day, cardiomagnil at a dose of 75 
mg/day, 10 mg of rosuvastatin. Patients of the 
control group (n=15) did not take rosuvastatin.
Patients were examined before and 12 days 
after treatment, therapy included the assessment 
of respiratory symptoms on a scale from 0 (no 
symptoms) to 3 (considerably severe symptoms). 
The degree of dyspnea was assessed using a 
modified scale of dyspnea (shortness of breath), 
MRC (Medical Research Counsil Dyspnoea 
Scale) [13]. Exercise tolerance was studied by 
a six-minute walk test (SMWT), which was 
conducted according to standard procedures.
The distance that a patient covers over the 
period 6 minutes was taken into account. The 
level of cholesterol, LDL, HDL was determined. 
The respiratory function was defined: FEV 1 
(forced expiratory volume in the 1st second), 
FEV1/FVC – Gaensler index (GI), Tiffeneau 
index modification FEV1/VC [14].
The average frequency of exacerbations 
during the previous year has been evaluated by a 
retrospective study of medical history.
Statistical analysis was performed using Excel 
7.0 editor. The results are given in the tables as 
the arithmetic average ± standard deviation (M 
± m) [15]. In order to evaluate the differences 
in performance as compared with the original 
data, Student’s t-test was used. A significant 
difference was considered with the error 
probability p<0.05.
Results
After the treatment of patients in both 
groups, the improvement in clinical status was 
detected due to decreased severity of respiratory 
symptoms: cough, sputum, dyspnea, as well 
as increased exercise tolerance and improved 
laboratory and instrumental performance.
A. One of the patients, 54 years old, was 
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the main group, as one can see from TABLE 
2, there was a significant reduction in blood 
levels of total cholesterol, triglycerides, LDL and 
increase in HDL (p<0.01) (TABLE 2).
The retrospective study of the case history 
(1.6 ± 0.48) revealed that the frequency of 
exacerbations in the past year was observed from 
1 to 2 times per year.
Conclusions
1. Inclusion of rosuvastatin in the 
comprehensive treatment of patients with 
COPD in combination with IHD can reduce 
and stabilize the main clinical manifestation 
of this constellation of diseases through its 
pleiotropic action.
2. The frequency of exacerbations of COPD 
in patients with cardiovascular pathology with 
the use of statins is significantly reduced; thereby 
the quality of patients life is improved.
the patients of the main group had statistically 
significant decrease in the intensity of cough and 
quantity of sputum than patients in the control 
group (p<0.05).
Furthermore, the pattern has been observed 
in the analysis of tolerance to physical activity 
between these groups of patients. After treatment 
patients had the increased tolerance to physical 
activity, but the patients of group II did not have 
a substantial nature of this condition, whereas 
the patients of the main group had significantly 
higher index (p<0.05).
It should be noted that in patients of the 
main group after treatment there was significant 
reduction of wheezing by means of increased 
FEV1 and GI (p<0.05).
Having analyzed the lipid levels in patients 
from the main and control groups before and 
after treatment, the significant difference was 
observed. Thus, after treatment in patients of 
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Table 1. Clinical and instrumental indicators in patients with COPD of В group in the combination with IHD, FC II.
Indicators
The I group (main) Group II (control)
Before treatment After treatment Before treatment After treatment
Cough (scores) 2.2 ± 0.13 1.75 ± 0.05*# 2.3 ± 0.13 1.9 ± 0.06*
Sputum (scores) 2.32 ± 0.17 1.61 ± 0.06*# 2.4 ± 0.16 1.78 ± 0.07*
Breathlessness (scores) 2.33 ± 0.12 1.83 ± 0.10* 2.27 ± 0.11 1.82 ± 0.10*
6-minute test (m) 411.47 ± 20.57 467.17 ± 19.35* 409.20 ± 20.46 453.47 ± 18.58
FEV1,% 56.23 ± 3.01 65.57 ± 3.27* 55.51 ± 2.98 62.8 ± 3.02
GI 62.7 ± 3.76 72.1 ± 3.61* 63.33 ± 3.8 70.26 ± 3.51
* (р<0.05 – р<0.001) significant difference of indicators in the dynamics of treatment; 
# (р<0.05) significant difference of indicators between the groups after treatment.
Table 2. Lipid profile indicators in patients with COPD of B group in the combination with IHD, FC II.
Lipid profile indicators
The I group (main) Group II (control)
Before treatment After treatment Before treatment After treatment
Cholesterol 5.88 ± 0.35 4.20 ± 0.25*# 5.77 ± 0.35 5.75 ± 0.35
Triacylglycerol 2.17 ± 0.11 1.68 ± 0.08*# 2.14 ± 0.11 2.16 ± 0.08
LDL 3.38 ± 0.20 2.43 ± 0.15*# 3.25 ± 0.20 3.23 ± 0.19
HDL 0.95 ± 0.05 1.16 ± 0.06* 1.06 ± 0.05 1.05 ± 0.05
*(р<0.01 – р<0.001) significant difference of indicators in the dynamics of treatment;
#(р<0.001) significant difference of indicators between the groups after treatment.
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